Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High- Risk Allogeneic Transplant Recipients  Sheila Serafino, Navneet S. Majhail,

Slides:



Advertisements
Similar presentations
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
How to Treat MDS without Stem Cell Transplantation
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants  Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)  Nelli Bejanyan, Brian J.
Biology of Blood and Marrow Transplantation
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Access to Hematopoietic Cell Transplantation in the United States
Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia 
Geoffrey Barkley, LCSW, PhD, Julie Perry, M.Div, Chaplaincy 
Navneet S. Majhail, Elizabeth A. Murphy, Nancy A
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 
Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)  Tania.
Treatment of Severe Mucositis Pain with Oral Ketamine Mouthwash
Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival  Ashok Srinivasan, William Mitchell,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL)  Deepa Jagadeesh, MD, MPH, Lisa.
A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal.
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Estimating Propensity Scores for the Receipt of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Outcomes Research Using Claims Data: A Machine.
Impact of Extremely Long Driving Distance on Distress and Physical Function in Hematopoietic Cell Transplant Recipients  Rahul Banerjee, Jean C. Yi, Navneet.
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe  Shahram.
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Infection Prevention - Visitors and the Best of Intentions
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study  Debbie Bates, Brian Bolwell, Navneet.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?  Melhem.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
A Successful Approach to Decreasing Central Line Associated Blood Stream Infections  Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children  Zühre Kaya, Daniel J. Weiner, Deniz.
Sonata Jodele, Kejian Zhang, Christopher E. Dandoy, Kasiani C
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Gerard Socié, K. Scott Baker, Smita Bhatia 
Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant.
Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation
Symmetry Analysis of the T Cell Receptor Beta VJ Segment Usage in Allogeneic Stem Cell Transplantation  Jeremy A. Meier, Mohamed Fawaz, Masoud Manjili,
Philippe Armand, MD, PhD, Haesook T
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Blood and Marrow Transplant Handbook
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic.
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation  Nikhil Dole, Nathan Luebbering, Nicholas.
In Memoriam: E. Donnall Thomas
Presentation transcript:

Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High- Risk Allogeneic Transplant Recipients  Sheila Serafino, Navneet S. Majhail, Julie Curtis, Laura Bernhard, Sharon Caroniti, Ronald M. Sobecks, Jamie Elberson, Brittany Hodgeman, Jamie Starn, Victoria Winslow, Betty Ky Hamilton  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages S451-S452 (March 2017) DOI: 10.1016/j.bbmt.2016.12.535 Copyright © 2016 Terms and Conditions

Figure 1 100 day high risk allo review. Biology of Blood and Marrow Transplantation 2017 23, S451-S452DOI: (10.1016/j.bbmt.2016.12.535) Copyright © 2016 Terms and Conditions

Figure 2 High risk allos at day +100. Biology of Blood and Marrow Transplantation 2017 23, S451-S452DOI: (10.1016/j.bbmt.2016.12.535) Copyright © 2016 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.